| [1] |
Chernock RD, Perry A, Pfeifer JD, et al.Receptor tyrosine kinases in sinonasal undifferentiated carcinomas-evaluation for EGFR, c-KIT, and HER-2/neu expression[J].Head Neck, 2009, 31(7):919-927.
|
| [2] |
Cuadros M, Talavera P, López FJ, et al.Real-time RT-PCR analysis for evaluating the HER-2/neu status in breast cancer[J].Pathobiology, 2010, 77(1):38-45.
|
| [3] |
Davoli A, Hocevar BA, Brown TL.Progression and treatment of HER-2-positive breast cancer[J].Cancer Chemother Pharmacol, 2010, 65(4):611-623.
|
| [4] |
Chang H.RNAi-mediated knockdown of target genes: a promising strategy for pancreatic cancer research[J].Cancer Gene Ther, 2007, 14(8):677-685.
|
| [5] |
Strand SP, Danielsen S, Christensen BE, et al.Influence of chitosan structure on the formation and stability of DNAchitosan polyelectrolyte complexes[J].Biomacromolecules,2005, 6(6):3357-3366.
|
| [6] |
Choudhury A, Charo J, Parapuram SK, et al.Small interfering RNA (siRNA) inhibits the expression of the HER-2/neu gene,upregulates HLA class I and induces apoptosis of HER-2/neu positive tumor cell lines[J].Int J Cancer, 2004, 108(1):71-77.
|
| [7] |
Katas H, Alpar HO.Development and characterisation of chitosan nanoparticles for siRNA delivery[J].J Control Release, 2006, 115(2):216-225.
|
| [8] |
徐海涛, 杜杰, 董新舒.Doxycycline 抑制大肠癌LS174T 细胞侵袭的体外实验研究[J].中国肿瘤临床, 2007, 34(11):625-628.
|
| [9] |
Kong A, Calleja V, Leboucher P, et al.HER-2 oncogenic function escapes EGFR tyrosine kinase inhibitors via activation of alternative HER receptors in breast cancer cells[J].PLoS One, 2008,3(8):e2881.
|
| [10] |
Mehra R, Burtness B.Antibody therapy for early-stage breast cancer: trastuzumab adjuvant and neoadjuvant trials[J].Expert Opin Biol Ther, 2006, 6(9): 951-962.
|
| [11] |
Romond EH, Perez EA, Bryant J, et a1.Trastuzumab plus adjuvant chemotherapy for operable HER-2-positive breast cancer[J].N Engl J Med, 2005, 353(16): 1673-1684.
|
| [12] |
Harris LN, You F, Schnitt SJ, et al.Predictors of resistance to preoperative trastuzumab and vinorelbine for HER-2-positive early breast cancer[J].Clin Cancer Res, 2007, 13(4):1198-1207.
|
| [13] |
Valabrega G, Montemurro F, Aglietta M.Trastuzumab: mechanism of action, resistance and future perspectives in HER-2-overexpressing breast cancer[J].Ann Oncol, 2007, 18(6):977-984.
|
| [14] |
Lau A.RNA interference in practice[J].Comp Funct Genomics,2005, 6(5-6):320-322.
|
| [15] |
Faltus T, Yuan J, Zimmer B, et al.Silencing of the HER-2/neu gene by siRNA inhibits proliferation and induces apoptosis in HER-2/neu-overexpressing breast cancer cells[J].Neoplasia, 2004, 6(6):786-795.
|
| [16] |
Yang G, Cai KQ, Thompson-Lanza JA, et al.Inhibition of breast and ovarian tumor growth through multiple signaling pathways by using retrovirus-mediated small interfering RNA against HER-2/neu gene expression[J].J Biol Chem, 2004,279(6):4339-4345.
|
| [17] |
程联胜, 查昭, 席甲甲, 等.慢病毒介导的RNA 干涉对乳腺癌SKBR3 细胞HER-2 受体的下调及生长抑制[J].中国生物工程杂志, 2007, 27(2):1-8.
|
| [18] |
Faltus T, Yuan J, Zimmer B, et al.Silencing of the HER-2/neu gene by siRNA inhibits proliferation and induces apoptosis in HER2/neu-overexpressing breast cancer cells[J].Neoplasia,2004,6(6):786-795.
|
| [19] |
Tan ML, Choong PF, Dass CR.Cancer, chitosan nanoparticles and catalytic nucleic acids[J].J Pharm Pharmacol,2009, 61(1):3-12.
|
| [20] |
Schmitz T, Bravo-Osuna I, Vauthier C, et al.Development and in vitro evaluation of a thiomer-based nanoparticulate gene delivery system[J].Biomaterials, 2007, 28(3):524-531.
|